Centaurus Financial’s Insight Molecular Diagnostics IMDX Stock Holding History

Centaurus Financial’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3	Closed	–	–	1544
2018 Q2	$0	Buy	+3	New	+$148	﹤0.01%	2344

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Centaurus Financial's IMDX Position: Q3 2018 in Review

Centaurus Financial sold out of Insight Molecular Diagnostics (IMDX) in Q3 2018, closing a stake of 3 shares.

Centaurus Financial first reported a position in IMDX in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 26 funds tracked by Wall St. Rank hold IMDX as of Q3 2018.

Centaurus Financial reported no remaining Insight Molecular Diagnostics position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 3 Insight Molecular Diagnostics shares in Q3 2018.
Centaurus Financial first reported a position in Insight Molecular Diagnostics in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Insight Molecular Diagnostics position peaked at $0 in Q2 2018.
26 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.